The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus

Metabolism, Journal Year: 2024, Volume and Issue: 161, P. 156028 - 156028

Published: Sept. 11, 2024

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 28, 2024

Language: Английский

---

Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 1623 - 1638

Published: Feb. 1, 2025

Objective: Hypertension development and progression are largely influenced by inflammation, which plays a critical role activating the immune system causing damage to vascular endothelium. Metabolic dysfunction-associated fatty liver disease (MAFLD) is also associated with chronic low-grade drives via metabolic imbalances adipose tissue dysfunction. This study investigates relationship between inflammatory indices MAFLD in hypertensive patients assesses predictive accuracy of these for MAFLD. Methods: We performed cross-sectional analysis involving 34,303 from Chinese hospital-based registry. The diagnosis was established using dysfunction criteria alongside evidence hepatic steatosis confirmed through imaging. Complete blood counts were used calculate indices, including monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), systemic response index (SIRI), immune-inflammation (SII), aggregate inflammation (AISI). To assess MAFLD, multivariable logistic regression adjustments potential confounders. diagnostic performance analyzed receiver operating characteristic (ROC) curves area under curve (AUC) calculations. Results: Patients exhibited significantly elevated levels all compared those without. After adjustment, each standard deviation increase AISI, SIRI, SII 74%, 62%, 58% increased odds respectively. AUC AISI 0.659, indicating moderate accuracy. AUCs SIRI 0.626 0.619, respectively, while NLR, PLR, MLR had lower 0.593, 0.558, 0.589, Conclusion: In patients, especially show strong association their utility risk stratification within clinical settings. Further research needed evaluate effectiveness markers management Keywords: metabolic-dysfunction-associated disease, hypertension,

Language: Английский

---

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta‐analysis

Liver International, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 11, 2024

Abstract Background Previous studies have reported an association between metabolic dysfunction‐associated steatotic liver disease (MASLD) and the risk of serious bacterial infections. However, magnitude whether this varies with severity MASLD remains uncertain. We performed a meta‐analysis observational to quantify infections requiring hospital admission. Methods systematically searched PubMed, Scopus, Web Science Embase from database inception 1 April 2024, using predefined keywords identify examining among individuals without MASLD. was diagnosed biopsy, imaging or International Classification Diseases codes. Meta‐analysis random‐effects modelling. Results identified six cross‐sectional two prospective cohort aggregate data on ~26.6 million individuals. significantly associated higher odds (pooled ratio 1.93, 95% confidence interval [CI] 1.44–2.58; I 2 = 93%). showed that MAFLD increased developing hazard 1.80, CI 1.62–2.0; 89%). This further across MASLD, especially fibrosis 2.42, 1.89–2.29; 92%). These results remained significant after adjusting for age, sex, obesity, diabetes other potential confounders. Sensitivity analyses did not modify these findings. The funnel plot reveal any publication bias. Conclusions shows

Language: Английский

---

Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis

Internal and Emergency Medicine, Journal Year: 2024, Volume and Issue: 19(6), P. 1745 - 1755

Published: July 11, 2024

Epidemiological studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of urolithiasis. However, magnitude whether this varies with severity MASLD remains uncertain. We performed a meta-analysis observational to quantify systematically searched PubMed, Scopus, Web Science from database inception March 31, 2024, using predefined keywords identify relevant in which imaging methods or survey questionnaires diagnosed Meta-analysis was random-effects modelling. identified seven cross-sectional one prospective cohort study aggregate data on 248,936 adults different countries. significantly associated increased prevalent urolithiasis (pooled odds ratio 1.87, 95% CI 1.34-2.60; I

Language: Английский

---

Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome”

Frontiers in Clinical Diabetes and Healthcare, Journal Year: 2025, Volume and Issue: 5

Published: Jan. 8, 2025

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes chronic globally. In 2020, a new terminology, namely "metabolic dysfunction-associated disease" (MAFLD), was proposed (1). Cardiometabolic criteria have been added in updated definition to highlight elevated cardiovascular risk these patients. The revised better emphasizes central role metabolic dysfunction development and progression this highly prevalent condition. From morbidity standpoint, both definitions are associated with an increased developing diabetes, disease, renal dysfunction. study 6873 individuals 4.6-year follow-up, associations MAFLD NAFLD kidney (CKD), (CVD) were similar (2). Epidemiological evidence indicates that not only liver-related complications, but also increases possibility several extra-hepatic diseases, including new-onset type 2 diabetes (T2DM) as well adverse outcomes (3). Metabolic disorders, overweight/obesity, T2DM, hypertension, dyslipidemia often systemic organ dysfunction, thereby suggesting could occur (Figure 1). novel understanding underscores bidirectional relationship between hepatic steatosis continuum.The association intriguing has highlighted recent years. be independently CKD (4). Parvanova colleagues investigated prevalence prediabetes, visceral obesity, preserved function, explored whether hyperfiltration, early sign damage (5). Renal hyperfiltration generally defined estimated glomerular filtration rate (eGFR) standard deviations above age- sex-specific mean, i.e.: >98th percentile. They analyzed data from more than 6000 Spanish civil servants, aged 18-65 years, fasting plasma glucose ≥ 100 ≤ 125 mg/dL (prediabetes). Approximately 4000 patients (62.9%) had MAFLD, 330 (4.9%) hyperfiltration. frequent without (86.4% vs 61.7%, P < 0.001). More half subjects 60 ml/min presented Interestingly, pathophysiologic basis altered function still fully unraveled. A finding dysregulation (6). It regarded by some manifestation syndrome (MetS), Heightened heightened inflammation, hemodynamics, proinflammatory markers, endothelial may all playing part (7). setting oxidative stress chronically abnormal adipokine profile, low-grade, subclinical inflammation promotes lipid accumulation atherogenic ("lipotoxicity"). regard, roles two key adipocytokines worth mentioning. Increased leptin secretion steatohepatitis, concomitant reduction adiponectin, which anti-inflammatory anti-atherogenic properties (8). fat deposition enhances release tumor necrosis factor-a (TNF-a) interleukin-6 (IL-6)(9). aforementioned factors shown contribute likelihood involvement (10). share factors, insulin resistance (IR), impaired tolerance, dyslipidemia, hypertension. Abbate et al. found dysglycemia (11). reported averaged 19.3%, progressively 14.7% 33.2% 48.9% normoglycemia, prediabetes respectively. Chen aimed clarify incident end-stage (ESRD) prospectively cohort 337,783 UK Biobank participants over median duration 12.8 years (12). Participants twice likely develop ESRD, ESRD remained significant non-CKD participants. Since IR accompaniment it surprising T2DM shows epidemiologic overlap latter. Worldwide, 18%-33% while up 66%-83% those varying degrees (13,14). Clinical improvements can favorably impact (15).Studies coexistence predicts ischemic heart (IHD) or alone (16). addition, combination abdominal obesity of, mortality from, CKD. retrospective 9161 National Health Nutrition Examination Surveys III (NHANES III) 1988 1994, abdominally obese group highest all-cause disease-specific during 30-year follow-up period (17). Abdominal therefore serve mediator CKD.Ascertaining fibrosis obvious clinical importance. respect, exhibited greater incidence compared (75.6% vs. 24.4%) (18). Liver assessed transient elastography albuminuria (19). noteworthy predictor (20). Having CKD, we would like recommend aggressive measures order natural history "MAFLD-Renal Syndrome". main interventions listed Table 1. Firstly, primary importance identification reversible stages, population increasing rates cannot over-emphasized. This requires high index suspicion involves screening asymptomatic high-risk for condition using approved tools. diagnosis presence its should promptly followed evaluation Such strategy justified based on showing epidemiologic, pathophysiologic, conditions. reasonable employ sensitive measurements damage, such microalbuminuria, emerging biomarkers nystatin C. Lifestyle dietary modifications, weight loss, physical activity beneficial amelioration obesity-metabolic form therapeutic cornerstone management (21). Pharmacologic at loss helpful kidneys, although detailed review beyond scope paper. There preliminary supporting use nutraceutical approaches certain MiRNAs mitigating deleterious milieu modifying gene expression steatohepatitis (22,23). thyroid hormone receptor activator resmetirom drug reduce treat noncirrhotic hepatitis moderate-to-advanced (24); however, unknown. evident preventive aspects intervention reducing burden MAFLD. Future efforts need directed investigating targeting unique hepatorenal pathways operate evolving relationship. context areas research therapeutics include following: 1) potential renin-angiotensin system genesis (25); 2) immune mechanisms antigen-activated CD8+ T cells, immune-modulating agents, pathogenesis MAFLD-associated (26), 3) applicability promising biomarkers, injury molecule-1 (KIM-1) liver-type acid binding protein (L-FABP), detection surveillance (27).

Language: Английский

---

Metabolic dysfunction-associated fatty liver disease and risk of nephrolithiasis: a sizeable cross-sectional study

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 21, 2025

Objective Metabolic dysfunction-associated fatty liver disease (MAFLD) and nephrolithiasis are two common metabolic diseases, but their relationship has not yet been thoroughly studied. Therefore, this study aimed to explore the association between MAFLD assess effect of on risk nephrolithiasis. Materials methods This cross-sectional included 96,767 adults from China. All participants underwent medical examinations, including physical history tests, laboratory tests. Based ultrasound examination, were divided into non-MAFLD groups, severity steatosis was determined based images. The analyzed using a multivariate logistic regression model subgroup analysis performed. Results proportion with significantly higher in group compared non-nephrolithiasis (47.70% vs. 30.45%, P &lt; 0.001). Multivariate showed significant positive (adjusted OR =1.38, 95% CI : 1.29 1.47). Subgroup analyses indicated that, even after accounting for various factors such as age, diabetes, hypertension, obesity, lipid profiles, renal function, an increased remained consistent. Further revealed that male patients MAFLD, progressively increasing steatosis. adjusted multivariable odds ratios 1.43 (95% 1.33 1.53) mild, 1.48 1.32 1.67) moderate, 1.94 1.47 2.58) severe hepatic Conclusions found males substantially it is essential strengthen prevention screening individuals MAFLD. More research needed elucidate physiological pathological mechanisms

Language: Английский

---

Quantitative imaging using [18F]F-TZ3108 to assess metabolic-associated fatty liver disease progression and low-carbohydrate diet efficacy

Nuclear Medicine and Biology, Journal Year: 2025, Volume and Issue: 144-145, P. 108997 - 108997

Published: Jan. 22, 2025

Language: Английский

---

Inhibiting DPP4 activity protects hiPSC-derived steatotic HLCs by supporting fatty acid and purine metabolism and dampening inflammation

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Background Metabolic dysfunction-associated steatotic liver disease (MAFLD) has a high prevalence and co-morbidity for other diseases. Due to the complexity of this multifactorial disease, therapy options are still rather limited. We employed an in vitro pluripotent stem cell-based model decipher basic disease-associated molecular pathways study mode action potential drugs. Methods induced steatosis phenotype in human cell (iPSC) derived hepatocyte-like cells (HLCs) by oleic acid (OA)-feeding confirmed regulation clinically relevant NGS-based global transcriptomic analyses. Analysis secretome HLCs revealed Dipeptidyl peptidase 4 (DPP4) as key mediator disease. To further elucidate its role development MAFLD, we inhibited DPP4 activity with Vildagliptin (VILDA) analyzed transcriptome changes well specific gene protein expression steatosis-associated genes without inhibition. Results MAFLD-associated such PPAR- TNF signaling were differentially regulated hiPSC-derived HLCs. found increased hepatic secretion upon OA. Fatty purine metabolism inflammation response improved Conclusions Our HLC-model clinically-relevant association which foster MAFLD. Inhibiting VILDA partially relieved phenotype. Trial registration Not applicable Impact implications: Given difficulties identifying suitable anti-MAFLD drugs, novel systems urgently needed. reproduced DPP4-dependent aspects responded positively treatment. Further elucidation etiology MAFLD is warranted.

Language: Английский

---

Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(02), P. 1996 - 2004

Published: Jan. 1, 2025

Language: Английский

---